Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
Eur J Drug Metab Pharmacokinet
; 47(3): 441, 2022 May.
Article
en En
| MEDLINE
| ID: mdl-35258796
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2022
Tipo del documento:
Article